Association of the treatment with 5 alpha-reductase inhibitors with the psychological well-being of patients with benign prostate hyperplasia

Sofronievska, Maja (2022) Association of the treatment with 5 alpha-reductase inhibitors with the psychological well-being of patients with benign prostate hyperplasia. In: 39 International Scientific Conference: Knowledge in Practice, 15 – 18 Dec 2022, Bansko, Bulgaria.

	Text PROGRAMA_BANSKO_2022.pdf - Additional Metadata Download (341kB)
	Text Association_PHQ_DHEA.pdf - Presentation Download (527kB)

Abstract

Benign prostatic hyperplasia is defined as a disorder, which has different ways of treatment depending on the symptomatology, the response to drug therapy, and the occurrence of complications. Pharmacological treatment of benign prostatic hyperplasia involves the use of mainly two groups of drugs: alpha 1 blockers and 5 alpha-reductase inhibitors (5ARIs). Side effects commonly occur during treatment with 5ARIs such as erectile dysfunction, decreased libido, and deterioration of psychological well-being. This paper aims to determine the association between DHEAS deficiency and the occurrence of side effects of 5ARI therapy that relate to the psychological well-being of patients with BPH. The analysis included 250 patients with benign prostatic hyperplasia (BPH), of whom 130 were treated with an alpha 1 blocker, while 120 patients were treated with a combination of tamsulosin and 5ARIs. The evaluation was conducted through questionnaires: IPSS (International Prostate Scoring System) to quantify BPH symptoms and PhQ-9 questionnaire for self-evaluation of depressive symptoms. The results showed that impaired psychological well-being occurred in 26 patients (22.5%) in the study group after 6- and 12-month therapy, which was statistically significant in this group (p<0.05). In these patients, there were also initially reduced serum values of dehydroepiandrosterone sulfate (DHEAS) (p<0.05). In this analysis, we concluded that the occurrence of impaired psychological well-being in patients treated with 5ARIs correlates with initially lower serum values of DHEAS before the start of therapy, which should be taken into account when using these medications

Item Type:	Conference or Workshop Item (Lecture)
Subjects:	Medical and Health Sciences > Clinical medicine Medical and Health Sciences > Health sciences
Divisions:	Faculty of Medical Science
Depositing User:	Maja Sofronievska
Date Deposited:	26 Dec 2022 12:35
Last Modified:	26 Dec 2022 12:35
URI:	https://eprints.ugd.edu.mk/id/eprint/30792

Actions (login required)

View Item